cilostazol has been researched along with Tauopathies in 2 studies
Tauopathies: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schaler, AW | 1 |
| Myeku, N | 1 |
| Lee, HR | 1 |
| Shin, HK | 1 |
| Park, SY | 1 |
| Kim, HY | 1 |
| Lee, WS | 1 |
| Rhim, BY | 1 |
| Hong, KW | 1 |
| Kim, CD | 1 |
2 other studies available for cilostazol and Tauopathies
| Article | Year |
|---|---|
Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline.
Topics: Animals; Cilostazol; Cognitive Dysfunction; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Male; | 2018 |
Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: targeting for cilostazol.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western | 2014 |